Intellia starts launch readiness for CRISPR gene therapy lonvo-z ahead of PDUFA
Intellia has completed its field organization deployment and strengthened engagement with payers for its HAE treatment lonvo-z. The stock is reacting positively to the data ahead of a March 10, 2027 PDUFA date.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed